Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. Its lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer, as well as advanced or metastatic triple negative breast cancer in collaboration with Pfizer Inc. The company has research and development collaboration agreement with National Cancer Institute, and licensing agreement with Newsoara to develop ZEN-3694, as well as with University of California. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. The company was incorporated in 2013 and is headquartered in Calgary, Canada.